I take 1 cup of Pom Juice most days based on the study attached. Doesn't taste great but I mix it with 1/2 c of Beet Juice. All organic. I have seen some talk about using the supplement Pomi-t. When I read the studies, too my non-scientific brain, it certainly looks like Pom Juice is the better of the two. However, not sure what all the P values mean, etc. I was hoping some of the science greats in the group can give me insight as to what shows better based on these. Trying to keep the BCR away if possible. Any help is appreciated. See below.
POMI-T
Methods
The researchers recruited 203 men aged 53 to 89 years with prostate cancer proven by biopsy. 59% of the men had not yet undergone any treatment and were being followed closely with periodic PSA tests (Active surveillance), while 41% had already had a radical intervention (radiotherapy or surgery and radiotherapy) but had relapsed with significantly climbing PSA levels. Men were randomly assigned to receive either the twice-daily oral capsule containing a blend of purified, polyphenol-rich whole foods, or a similar-looking placebo for 6 months. At baseline, there were no significant differences between the two groups. Neither the doctors supervising the trial, the men involved or statisticians analysing the data knew which men were taking a placebo or the Pomi-T.
Results
Percentage rise in PSA: The median percentage change in PSA for patients in the Pomi-T group was a rise of 14.7% (95% CI 3.4%-36.7%), compared to a rise of 78.5% (95% confidence interval 48.1% -115.5%) for patients in the placebo group. The median PSA increased at a significantly slower rate in the Pomi-T group compared to men taking a placebo (difference of 63.8% ANCOVA, p=0.0008).
Percentage of men having a stable or a lower PSA at the end of the study: At trial completion, the number of men with a stable PSA or a lower PSA was 61 (46%) in the Pomi-T group, compared to 9 (14%) in the placebo group. This difference was statistically significant (Chi-squared value with 1 degree of freedom = 19.58, p=0.000010).
Percentage of men in whom Pomi-T prevented a change in management: 114 (92.6%) men in the Pomi-T group continued surveillance or WW at the end of their involvement in the study, as opposed to 38 (74%) in the placebo group. This difference of 18.6% was statistically significant (p=0.01).
Subgroup analysis: There was no significant difference in the median change in PSA from baseline to 6 months in either the Pomi-T or placebo group between any of the pre-determined subgroups (BMI, Gleason grade, age or treatment category). There were no significant differences at the beginning or end of the study between the subgroups for measures of cholesterol, blood pressure, serum glucose or C-reactive protein.
Conclusions
In this study, it was shown that men taking the whole food supplement (Pomi-T) had a significantly lower median percentage rise in PSA compared to men taking a placebo (P<0.0001). The difference in percentage rise in PSA between these groups from the start to end of the study was large (63.8%), and as the patient characteristics were well-balanced and the trial had sufficient numbers to ensure adequate statistical power, the results of this study offer clinically meaningful guidance for men contemplating nutritional supplements after prostate cancer. Future trials will look at continuing the intervention for longer and include men with different stages of the disease.
POMEGRANITE JUICE
Purpose: Phytochemicals in plants may have cancer preventive benefits through antioxidation and via gene-nutrient interactions. We sought to determine the effects of pomegranate juice (a major source of antioxidants) consumption on prostate-specific antigen (PSA) progression in men with a rising PSA following primary therapy.
Experimental design: A phase II, Simon two-stage clinical trial for men with rising PSA after surgery or radiotherapy was conducted. Eligible patients had a detectable PSA > 0.2 and < 5 ng/mL and Gleason score < or = 7. Patients were treated with 8 ounces of pomegranate juice daily (Wonderful variety, 570 mg total polyphenol gallic acid equivalents) until disease progression. Clinical end points included safety and effect on serum PSA, serum-induced proliferation and apoptosis of LNCaP cells, serum lipid peroxidation, and serum nitric oxide levels.
Results: The study was fully accrued after efficacy criteria were met. There were no serious adverse events reported and the treatment was well tolerated. Mean PSA doubling time significantly increased with treatment from a mean of 15 months at baseline to 54 months posttreatment (P < 0.001). In vitro assays comparing pretreatment and posttreatment patient serum on the growth of LNCaP showed a 12% decrease in cell proliferation and a 17% increase in apoptosis (P = 0.0048 and 0.0004, respectively), a 23% increase in serum nitric oxide (P = 0.0085), and significant (P < 0.02) reductions in oxidative state and sensitivity to oxidation of serum lipids after versus before pomegranate juice consumption.
Conclusions: We report the first clinical trial of pomegranate juice in patients with prostate cancer. The statistically significant prolongation of PSA doubling time, coupled with corresponding laboratory effects on prostate cancer in vitro cell proliferation and apoptosis as well as oxidative stress, warrant further testing in a placebo-controlled study.